1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes
FOLAND-ROSS L, BUCKINGHAM B, MAURAS N, ARBELAEZ A, WHITE N, AYE T, WILSON D, TAMBORLANE W, WEINZIMER S, TSALIKIAN E, TANSEY M, CATO A, HERSHEY T, FOX L, TONG G, ENGLERT K, MAZAIKA P, REISS A. 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1382-p.Peer-Reviewed Original ResearchDefault mode networkExecutive control regionsDiabetes careMedtronic MiniMedSpouse/partnerGreater activationEunice Kennedy Shriver National InstituteLess suppressionEffects of dysglycemiaAdvisory PanelEli LillySimilar task performanceExecutive control areasParent-report measuresTakeda Pharmaceutical Company LimitedNondiabetic childrenT1D groupHbA1c levelsNondiabetic controlsSlower processing speedT1D onsetHigher HbA1cChild healthResearch supportMulti-site study209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet)
ARBELAEZ A, O’DONOGHUE S, MAURAS N, BUCKINGHAM B, WHITE N, WEINZIMER S, AYE T, TSALIKIAN E, WILSON D, TAMBORLANE W, TANSEY M, CATO A, HERSHEY T, FOX L, ENGLERT K, REISS A. 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet). Diabetes 2019, 68 DOI: 10.2337/db19-209-or.Peer-Reviewed Original ResearchDiabetes careNondiabetic controlsVoxel-based morphometryMedtronic MiniMedWhite matterSubcortical GMSpouse/partnerEarly-onset type 1 diabetesEunice Kennedy Shriver National InstituteAge-matched nondiabetic controlsEarly-onset T1DTime of diagnosisWorse glycemic controlType 1 diabetesEffects of T1DBasal ganglia regionsAdvisory PanelRapid brain maturationWhite matter areasEli LillyGray matter volumeGray matter regionsTakeda Pharmaceutical Company LimitedGlycemic exposureT1D children1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control